Although INSTI-based regimens are highly efficacious for viral suppression, they appear to
cause more weight gain and treatment emergent obesity than non-INSTI-based regimens …

The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Background Initiation of antiretroviral therapy (ART) often leads to weight gain. While some
of this weight gain may be an appropriate return-to-health effect, excessive increases in …

Importance Data on the use of antiretroviral drugs, including new drugs and formulations, for
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …

Introduction Weight gain following antiretroviral therapy (ART) initiation is common,
potentially predisposing some persons with HIV (PWH) to cardio‐metabolic disease. We …

Introduction: Although weight gain has been reported with the use of integrase strand
transfer inhibitors (InSTI), concurrent use of tenofovir alafenamide (TAF) has been implicated …

Abstract Purpose of Review The proportion of overweight and obese persons with HIV
(PWH) has increased since the introduction of antiretroviral therapy (ART). We aim to …

Introduction: Efficient antiretroviral-treatment (ART) generally allows control of HIV infection.
However, persons-living-with-HIV (PLWH), when aging, present a high prevalence of …

Background Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is
recommended for human immunodeficiency virus (HIV) management. Although studies …

Background Integrase strand transfer inhibitor (INSTI)–based combination antiretroviral
therapy (cART) is associated with greater weight gain among persons with human …